NO985522D0 - Prevention of graft-versus-host disease with T cells including polynucleotides encoding negative selective markers - Google Patents
Prevention of graft-versus-host disease with T cells including polynucleotides encoding negative selective markersInfo
- Publication number
- NO985522D0 NO985522D0 NO985522A NO985522A NO985522D0 NO 985522 D0 NO985522 D0 NO 985522D0 NO 985522 A NO985522 A NO 985522A NO 985522 A NO985522 A NO 985522A NO 985522 D0 NO985522 D0 NO 985522D0
- Authority
- NO
- Norway
- Prior art keywords
- versus
- graft
- host disease
- host
- prevention
- Prior art date
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
- 208000024908 graft versus host disease Diseases 0.000 title abstract 4
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 210000001185 bone marrow Anatomy 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000002679 ablation Methods 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method of preventing graft-versus-host disease in a patient being treated for relapsed or persistent leukemia. The method comprises administering to a host allogeneic T-cells genetically engineered to include a polynucleotide encoding a negative selective marker. Prior to the occurrence of graft-versus-host disease, an interaction or chemotherapeutic agent is administered to the host, which kills the genetically engineered T-cells, thereby preventing the occurrence of graft-versus-host disease. Such method also may be employed in connection with the treatment of any disease or disorder wherein the treatment includes bone marrow ablation followed by the administration of a T-cell depleted bone marrow transplant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65645196A | 1996-05-31 | 1996-05-31 | |
| PCT/US1997/009040 WO1997045142A1 (en) | 1996-05-31 | 1997-05-28 | Prevention of graft-versus-host disease with t-cells including polynucleotides encoding negative selective markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO985522D0 true NO985522D0 (en) | 1998-11-26 |
| NO985522L NO985522L (en) | 1999-01-25 |
Family
ID=24633085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO985522A NO985522L (en) | 1996-05-31 | 1998-11-26 | Prevention of graft-versus-host disease with T cells including polynucleotides encoding negative selective markers |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0977595A4 (en) |
| JP (1) | JP2000511539A (en) |
| AU (1) | AU719930B2 (en) |
| CA (1) | CA2255941A1 (en) |
| IL (1) | IL127211A0 (en) |
| NO (1) | NO985522L (en) |
| NZ (1) | NZ333053A (en) |
| WO (1) | WO1997045142A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9705744D0 (en) * | 1997-03-20 | 1997-05-07 | Davies Alison M | Methods for selecting cells and their uses |
| US6565831B1 (en) | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| FR2780891A1 (en) * | 1998-07-10 | 2000-01-14 | Univ Paris Curie | EXCHANGE OF T LYMPHOCYTES |
| JP2002544174A (en) | 1999-05-07 | 2002-12-24 | ジェネンテック・インコーポレーテッド | Treatment of autoimmune diseases using antagonists that bind to B cell surface markers |
| ITMI991299A1 (en) * | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | USE OF ANTIBODIES AGAINST SURFACE ANTIGENS FOR THE TREATMENT OF DISEASE TRANSPLANT AGAINST GUESTS |
| ZA200203041B (en) | 1999-11-12 | 2003-12-09 | Oncolytics Biotech Inc | Viruses for the treatment of cellular proliferative disorders. |
| JP2009514627A (en) * | 2005-11-10 | 2009-04-09 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Reduce restenosis |
| JP5394932B2 (en) * | 2007-11-02 | 2014-01-22 | 日本ケミカルリサーチ株式会社 | Pharmaceutical composition containing human mesenchymal stem cells |
| RU2456924C1 (en) * | 2010-12-14 | 2012-07-27 | Федеральное государственное учреждение "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Method of predicting overall survival of patients with multiple myeloma |
-
1997
- 1997-05-28 IL IL12721197A patent/IL127211A0/en unknown
- 1997-05-28 AU AU30796/97A patent/AU719930B2/en not_active Ceased
- 1997-05-28 WO PCT/US1997/009040 patent/WO1997045142A1/en not_active Application Discontinuation
- 1997-05-28 EP EP97925747A patent/EP0977595A4/en not_active Withdrawn
- 1997-05-28 NZ NZ333053A patent/NZ333053A/en unknown
- 1997-05-28 JP JP09542889A patent/JP2000511539A/en active Pending
- 1997-05-28 CA CA002255941A patent/CA2255941A1/en not_active Abandoned
-
1998
- 1998-11-26 NO NO985522A patent/NO985522L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000511539A (en) | 2000-09-05 |
| NZ333053A (en) | 2000-06-23 |
| EP0977595A4 (en) | 2001-05-16 |
| CA2255941A1 (en) | 1997-12-04 |
| NO985522L (en) | 1999-01-25 |
| WO1997045142A1 (en) | 1997-12-04 |
| EP0977595A1 (en) | 2000-02-09 |
| AU719930B2 (en) | 2000-05-18 |
| AU3079697A (en) | 1998-01-05 |
| IL127211A0 (en) | 1999-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0313197A (en) | Cytotoxic agents containing potent taxanes and their therapeutic use | |
| BRPI0108977B8 (en) | azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof | |
| IL197686A0 (en) | Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith | |
| IE904281A1 (en) | Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals | |
| MY125921A (en) | Compositions containing organic compounds | |
| NZ517772A (en) | Cytotoxic agents comprising taxanes and their therapeutic use | |
| BR0309875A (en) | methods and compositions for treating peripheral nervous system disorders and novel compounds useful therefor | |
| CA2283430A1 (en) | Elimination of vapour anaesthetics from patients after surgical procedures | |
| ATE334985T1 (en) | COMPOUNDS, METHODS AND PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CELL DAMAGE SUCH AS DAMAGE TO NERVOUS OR VESSEL TISSUE | |
| EA200000468A1 (en) | THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY | |
| EA200100298A1 (en) | PHARMACEUTICAL PREPARATIONS WITH ADJUSTABLE LIBERATION CONTAINING THE INHIBITOR OF cGMP-PHOSPHODYSTRASE-5 | |
| PL365285A1 (en) | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs | |
| NO985522D0 (en) | Prevention of graft-versus-host disease with T cells including polynucleotides encoding negative selective markers | |
| GB2341605B (en) | Therapeutic systems | |
| IL157841A0 (en) | Activation of natural killer cells by adenosine a3 receptor agonists | |
| HUS1900041I1 (en) | Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation | |
| NZ511280A (en) | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists | |
| EP1413299A3 (en) | Use of deprenyl analogues to maintain, prevent loss, or recover nerve cell function | |
| NO995944L (en) | Antiarrhythmic mixture and methods of treatment | |
| AU617998B2 (en) | Anticoccidial composition | |
| ES2036560T3 (en) | A METHOD FOR PREPARING A SYNERGICALLY ACTIVE COMPOSITION FOR THE TREATMENT OF HYPERTENSION. | |
| ZA972601B (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
| EP1073436A4 (en) | IMPROVED METHOD FOR ERADICATION OF $i(HELICOBACTER PYLORI) | |
| HUP9903679A2 (en) | Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder | |
| ATE334686T1 (en) | COMPOSITION CONTAINING SPHINGOMYELIN FOR IMPROVEMENT OF TUMOR THERAPY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |